Palonosetron Versus Ramosetron for the Prevention of Postoperative Nausea and Vomiting
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
Ramosetron and palonosetron are more recently developed 5-hydroxytryptamine type 3 receptor
antagonists and this randomized double blind study was designed to compare efficacy of
ramosetron and palonosetron to prevent postoperative nausea and vomiting. Investigator
hypothesized that palonosetron would have stronger and longer lasting antiemetic effect
compared with ramosetron and evaluated the patients for the first 48 hours after surgery.